group
streptococci
identif
bacteri
strain
constitut
basic
tool
studi
epidemiolog
treatment
outcom
pharyngotonsil
streptococc
group
organ
classifi
serolog
group
au
accord
carbohydr
antigen
cell
wall
base
presenc
antigen
betahemolyt
group
streptococci
divid
type
subdivis
group
streptococci
made
basi
mprotein
dna
technolog
past
decad
result
classif
mtype
betahemolyt
group
streptococci
base
upon
sequenc
mtype
gene
emm
emmsequ
type
identifi
betahemolyt
group
streptococci
possess
multitud
extracellular
cellbound
virul
factor
aid
variou
stage
tissu
invas
respons
differ
diseas
manifest
cell
wall
mprotein
extend
alphahel
protein
anticomplementari
antiphagocyt
properti
consid
main
virul
determin
betahemolyt
group
streptococci
mprotein
interact
plasma
protein
immunoglobulin
g
fibrinogen
protein
abl
interfer
innat
adapt
host
immun
respons
recogn
decad
typespecif
antibodi
direct
toward
ntermin
part
mprotein
opson
protect
betahemolyt
group
streptococc
diseas
hyaluron
capsul
although
poorli
express
vitro
second
antiphagocyt
factor
betahemolyt
group
streptococci
tprotein
previous
implic
biolog
import
recent
shown
present
fimbriaelik
structur
betahemolyt
group
streptococci
probabl
play
role
tissu
adhes
pyrogen
exotoxin
erythrogen
toxin
superantigen
capabl
trigger
lymphocyt
releas
massiv
amount
cytokin
interleukin
therebi
gener
sever
symptom
fever
scarlatiniform
rash
tissu
necrosi
hypotens
organ
failur
cystein
proteas
ident
exotoxin
speb
accord
experiment
work
may
essenti
circulatori
shock
lung
damag
enzym
second
cystein
proteas
betahemolyt
group
streptococci
may
cleav
immunoglobulin
g
therebi
interf
immun
opson
betahemolyt
group
streptococci
streptolysin
capabl
lyse
erythrocyt
well
leukocyt
platelet
streptokinas
convert
plasminogen
plasmin
may
significantli
contribut
rapid
spread
betahemolyt
group
streptococci
within
infect
tissu
lyse
blood
clot
abil
betahemolyt
group
streptococci
especi
stationari
phase
invad
respiratori
epitheli
cell
recent
demonstr
betahemolyt
group
streptococci
mainli
extracellular
bacteria
specif
bind
fibronectin
protein
exist
human
blood
plasma
extracellular
matrix
betahemolyt
group
streptococci
may
effici
intern
human
mucos
cell
fibronectin
bound
bacteri
surfac
therebi
act
like
bridg
molecul
host
cell
integrin
turn
initi
uptak
process
lead
intern
sela
barzilai
found
betahemolyt
group
streptococc
strain
abl
surviv
day
insid
cultur
epitheli
cell
also
found
betahemolyt
group
streptococc
strain
patient
treatment
failur
harbour
internalizationassoci
gene
higher
preval
strain
recov
patient
streptococc
strain
success
erad
known
intern
host
cell
influenc
sever
betahemolyt
group
streptococc
infect
strain
streptococci
show
vari
capac
intern
intern
betahemolyt
group
streptococci
found
asymptomat
carrier
well
patient
pharyngotonsil
strain
patient
treatment
failur
exhibit
significantli
increas
abil
surviv
intracellularli
cultur
epitheli
cell
compar
strain
success
treat
patient
hand
betahemolyt
group
streptococc
strain
abl
intern
anim
model
less
abl
caus
seriou
diseas
betahemolyt
group
streptococci
without
intern
capac
betahemolyt
group
streptococci
strict
human
pathogen
give
rise
wide
rang
infecti
diseas
impetigo
pharyngotonsil
erysipela
may
compar
mild
effect
treat
antibiot
howev
sinc
late
rise
number
lifethreaten
invas
betahemolyt
group
streptococc
infect
encount
necrot
fasciiti
streptococc
toxic
shock
syndrom
streptococci
diseas
often
restrict
certain
mtype
particular
produc
power
superantigen
pyrogen
exotoxin
spea
surgic
intervent
often
need
case
necrot
fasciiti
howev
spite
antibiot
intens
care
mortal
high
patient
necrot
fasciiti
streptococc
toxic
shock
syndrom
acut
rheumat
fever
seriou
nonsuppur
complic
betahemolyt
group
streptococc
pharyngotonsil
lead
caus
acquir
heart
diseas
among
children
develop
countri
although
longer
signific
health
problem
socioeconom
advanc
countri
limit
outbreak
acut
rheumat
fever
occur
usa
acut
poststreptococc
glomerulonephr
major
caus
child
renal
failur
occur
throat
skin
infect
betahemolyt
group
streptococci
larg
epidem
still
occur
develop
countri
compar
sporad
case
develop
world
sign
symptom
acut
pharyngotonsil
includ
fever
throat
angina
red
tonsil
pharynx
tonsillar
exud
enlarg
tender
cervic
lymph
node
dysphagia
headach
concurr
symptom
respiratori
tract
eg
cough
rhinorrhea
indic
viral
origin
diseas
establish
betahemolyt
group
streptococc
throat
skin
infect
close
surround
patient
home
school
daycar
centr
increas
probabl
betahemolyt
group
streptococc
origin
infect
certain
symptom
pronounc
pharyngotonsil
betahemolyt
group
streptococc
origin
pharyngotonsil
anoth
etiolog
thu
high
degre
red
throat
fever
shorter
durat
symptom
seek
medic
care
correl
significantli
betahemolyt
group
streptococci
etiolog
socal
centor
criteria
wide
use
implic
betahemolyt
group
streptococci
adult
patient
follow
tonsillar
exud
tender
anterior
cervic
adenopathi
fever
histori
absenc
cough
three
criteria
met
posit
predict
valu
betahemolyt
group
streptococc
infect
find
howev
inconsist
although
clinic
pictur
may
guidanc
seldom
suffici
establish
reliabl
etiolog
diagnosi
pathognomon
sign
symptom
provid
definit
diagnosi
betahemolyt
group
streptococc
pharyngotonsil
diagnosi
depend
identif
bacterium
bacteri
identif
perform
obtain
throat
cultur
rapid
antigen
detect
test
good
view
pharynx
obtain
proper
sampl
techniqu
essenti
achiev
repres
sampl
specimen
obtain
tonsillar
surfac
betahemolyt
group
streptococci
pharyngotonsil
predominantli
local
tonsil
posterior
oropharyng
wall
rapid
antigen
test
requir
bacteria
requir
cultur
quantiti
sampl
materi
thu
influenc
sensit
specif
rapid
test
current
report
respect
asymptomat
carriag
stage
betahemolyt
group
streptococci
report
occur
adult
children
winter
season
although
estim
vari
consider
larg
outbreak
betahemolyt
group
streptococc
pharyngotonsil
carrier
rate
high
longitudin
studi
schoolchildren
found
period
child
carri
betahemolyt
group
streptococci
emm
type
averag
week
rang
week
mani
children
howev
experienc
sever
period
carriag
studi
frequent
exhibit
switch
emm
type
risk
becom
carrier
betahemolyt
group
streptococci
well
contract
pharyngotonsil
relat
period
time
spent
close
contact
patient
week
preced
onset
ill
reason
individu
becom
carrier
unknown
carrier
state
appear
rel
harmless
condit
probabl
result
clinic
infect
streptococci
present
low
number
probabl
support
persontoperson
transmiss
organ
howev
problem
aris
carrier
betahemolyt
group
streptococci
acquir
viral
pharyng
posit
test
betahemolyt
group
streptococci
rais
issu
antibiot
treatment
exampl
highlight
import
care
evalu
symptom
order
avoid
unnecessari
antibiot
treatment
correl
leukocytosi
increas
level
creactiv
protein
betahemolyt
group
streptococc
pharyngotonsil
report
wherea
investig
fail
verifi
relationship
serolog
test
antistreptolysin
antidnas
b
diagnost
valu
acut
pharyngotonsil
may
use
investig
complic
diseas
rheumat
fever
betahemolyt
group
streptococc
pharyngotonsil
selflimit
diseas
routin
use
penicillin
v
therefor
question
howev
betahemolyt
group
streptococci
amongst
virul
human
pathogen
patient
pharyngotonsil
caus
infect
bacterium
serious
affect
high
fever
dysphagia
sever
pain
although
major
patient
becom
free
symptom
within
week
irrespect
therapi
antibiot
treatment
pharyngotonsil
caus
betahemolyt
group
streptococci
significantli
shorten
durat
symptom
antibiot
treatment
may
also
extent
reduc
risk
purul
complic
peritonsil
otiti
sinus
acut
rheumat
fever
claim
major
patient
histori
pharyngotonsil
declin
acut
rheumat
fever
develop
world
may
inde
result
routin
antibiot
use
betahemolyt
group
streptococc
pharyngotonsil
support
present
principl
treatment
rheumat
fever
still
major
health
problem
mani
develop
countri
betahemolyt
group
streptococci
estim
eighth
common
sourc
global
mortal
caus
singl
pathogen
necrot
fasciiti
streptococc
toxic
shock
syndrom
howev
port
entri
betahemolyt
group
streptococci
seldom
report
pharyngotonsil
sum
reason
antibiot
treatment
betahemolyt
group
streptococc
pharyngotonsil
rapid
allevi
symptom
ii
reduc
spread
betahemolyt
group
streptococci
iii
reduc
risk
suppur
nonsuppur
complic
gener
agre
benefit
antibiot
treatment
outweigh
disadvantag
penicillin
v
peror
day
mg
kg
two
four
time
daili
current
antibiot
therapi
choic
betahemolyt
group
streptococc
pharyngotonsil
despit
year
use
penicillin
penicillinresist
betahemolyt
group
streptococc
strain
far
encount
possibl
explan
penicillin
resist
speci
compat
virul
phenotyp
penicillin
v
treatment
betahemolyt
group
streptococc
pharyngotonsil
treatment
period
least
day
impos
order
achiev
accept
low
recurr
rate
despit
absenc
penicillin
resist
treatment
failur
betahemolyt
group
streptococc
pharyngotonsil
high
second
cours
penicillin
v
treatment
follow
still
higher
failur
rate
case
necessit
tonsillectomi
cephalosporin
shown
effect
penicillin
v
treat
primari
betahemolyt
group
streptococc
pharyngotonsil
cephalosporin
may
enabl
shorter
treatment
regimen
penicillin
v
patient
may
need
dose
daili
cephalosporin
less
suscept
blactamas
produc
oral
bacteria
probabl
exert
lesser
impact
bacteriocinproduc
alphahemolyt
streptococci
throat
treatment
recurr
betahemolyt
group
streptococc
pharyngotonsil
clindamycin
instead
penicillin
v
seem
produc
significantli
better
clinic
outcom
may
result
intracellular
accumul
high
concentr
clindamycin
tonsillar
surfac
fluid
penicillin
v
result
narrow
antimicrobi
spectrum
absenc
penicillin
resist
among
betahemolyt
group
streptococci
still
regard
drug
choic
primari
betahemolyt
group
streptococc
pharyngotonsil
cephalosporin
clindamycin
appear
appropri
altern
patient
experienc
recurr
pharyngotonsil
penicillin
v
treatment
problem
frequent
recurr
betahemolyt
group
streptococc
pharyngotonsil
patient
sometim
resolv
perform
tonsillectomi
although
opinion
differ
benefit
risk
treatment
cochran
review
studi
fulfil
inclus
criteria
evalu
effect
tonsillectomi
adult
chronic
recurr
acut
pharyngotonsil
two
studi
fulfil
criteria
assess
benefit
tonsillectomi
children
chronic
recurr
acut
pharyngotonsil
limit
conclus
could
drawn
studi
studi
need
evalu
effect
tonsillectomi
relat
pharyngotonsil
possibl
factor
may
lead
recurr
penicillin
v
treatment
pharyngotonsil
includ
low
patient
complianc
reinfect
environ
erad
alfahemolyt
streptococci
inhibitori
effect
betahemolyt
group
streptococci
increas
betalactamaseproduc
bacteria
inactiv
drug
penicillintoler
streptococci
low
antibiot
concentr
site
infect
intracellular
betahemolyt
group
streptococci
surviv
therapi
tabl
treatment
betahemolyt
group
streptococc
pharyngotonsil
penicillin
v
result
rapid
recoveri
patient
often
free
symptom
day
treatment
may
consid
medic
unnecessari
prematur
discontinu
antibiot
treatment
rais
odd
treatment
failur
famili
member
close
contact
patient
betahemolyt
group
streptococcu
pharyngotonsil
often
infect
strain
recurr
may
caus
reinfect
individu
alphahemolyt
streptococci
produc
bacteriocin
inhibitori
activ
betahemolyt
group
streptococci
erad
alphahemolyt
streptococci
penicillin
v
theoret
reduc
bacteri
interfer
thu
increas
risk
treatment
failur
howev
investig
fail
show
lack
bacteri
interfer
relat
bacteri
treatment
failur
betahemolyt
group
streptococc
pharyngotonsil
hand
administr
alphahemolyt
streptococci
throat
follow
blactam
treatment
betahemolyt
group
streptococc
pharyngotonsil
abl
reduc
recurr
rate
howev
replac
treatment
alphahemolyt
streptococci
yet
commerci
avail
increas
blactamaseproduc
bacteria
inactiv
drug
treatment
penicillin
v
promot
select
bacteri
speci
produc
blactamas
conceiv
account
inactiv
penicillin
v
howev
studi
penicillin
v
vs
amoxicillin
clavulan
acid
treatment
pharyngotonsil
inconclus
gerber
et
al
studi
penicillin
v
cefadroxil
treatment
primari
betahemolyt
group
streptococcu
pharyngotonsil
found
evid
blactamas
produc
normal
pharyng
flora
relat
bacteri
treatment
failur
role
blactamas
treatment
failur
thu
remain
unclear
toler
blactam
antibiot
known
phenomenon
medic
import
speci
enterococcu
faecali
streptococcu
pneumonia
variou
alphahemolyt
streptococci
appear
account
failur
penicillin
therapi
arcanobacterium
haemolyticum
infect
penicillin
toler
betahemolyt
group
streptococci
suggest
account
failur
penicillin
v
treatment
betahemolyt
group
streptococc
pharyngotonsil
report
contradictori
conceiv
variabl
definit
well
technic
pitfal
method
use
exist
penicillin
toler
betahemolyt
group
streptococci
also
question
betahemolyt
group
streptococci
caus
acut
pharyngotonsil
mainli
present
secret
tonsillar
surfac
crypt
rather
parenchyma
penicillin
v
detect
tonsillar
surfac
fluid
major
patient
first
day
treatment
acut
betahemolyt
group
streptococcu
pharyngotonsil
despit
high
concentr
serum
rare
present
day
healthi
treat
subject
insuffici
concentr
antibiot
tonsillar
surfac
fluid
may
contribut
treatment
failur
betahemolyt
group
streptococc
pharyngotonsil
betahemolyt
group
streptococci
may
resid
epitheli
cell
pharyngotonsil
lesion
may
reach
penicillin
v
sterlund
et
al
found
betahemolyt
group
streptococci
intern
human
respiratori
epitheli
cell
grown
antibiot
supplement
medium
extern
soon
extracellular
antibiot
remov
extracellular
infect
develop
rapidli
thereaft
thu
respiratori
epitheli
cell
may
act
reservoir
intern
betahemolyt
group
streptococci
potenti
caus
infect
termin
penicillin
v
treatment
extent
epitheli
cellembed
betahemolyt
group
streptococci
caus
recurr
pharyngotonsil
penicillin
v
treatment
remain
determin
group
c
group
g
streptococci
may
caus
pharyngotonsil
especi
older
children
adult
rapid
test
detect
streptococc
group
avail
thu
bacteri
cultur
need
diagnosi
evid
suggest
group
c
group
g
streptococci
caus
acut
poststreptococc
glomerulonephr
rheumat
fever
hemolyticum
uncommon
caus
pharyngotonsil
often
associ
rash
may
mimic
scarlatina
diseas
found
commonli
individu
year
agegroup
incid
among
patient
pharyngotonsil
age
group
organ
must
cultur
specif
media
sensit
penicillin
sensit
macrolid
hemolyticumrel
pharyngotonsil
selflimit
known
complic
pharyngotonsil
caus
c
diphtheria
rel
common
world
war
ii
rapidli
declin
europ
sinc
time
vaccin
popul
diseas
rare
howev
c
diphtheriaerel
pharyngotonsil
uncommon
former
soviet
union
countri
incid
probabl
underreport
pharyngotonsil
caus
c
diphtheria
character
grey
membran
throat
larynx
around
nostril
bleed
occur
attempt
made
remov
membran
bacteria
produc
exotoxin
give
rise
myocard
neurolog
complic
paralysi
polyneuropathia
treatment
parenter
antibiot
specif
immunoglobulin
start
immedi
even
microbiolog
diagnosi
case
high
suspicion
c
diphtheriaerel
pharyngotonsil
angina
uncommon
infect
present
unilater
necrot
tonsil
caus
mix
anerob
aerob
flora
spirochet
bacteroid
streptococci
fusiform
bacteria
penicillin
drug
choic
patient
must
followedup
coupl
week
rule
malign
carcinoma
tonsil
show
similar
clinic
pictur
n
gonorrhoea
may
caus
pharyngotonsil
individu
practis
oral
sex
studi
patient
sore
throat
gener
medic
practic
found
preval
n
gonorrhoea
patient
genit
gonorrhoea
throat
cultur
posit
n
gonorrhoea
often
asymptomat
n
gonorrhoea
must
grown
specif
media
antibiot
treatment
need
prevent
transmiss
well
dissemin
organ
diseas
pharyngotonsil
involv
pneumonia
c
pneumonia
frequent
accompani
bronchiti
infect
two
bacteria
often
affect
children
young
adult
individu
becom
infect
epsteinbarr
viru
childhood
experi
subclin
infect
mild
pharyng
howev
onethird
individu
becom
infect
adolesc
develop
mononucleosi
syndrom
infecti
mononucleosi
system
diseas
character
pharyngotonsil
nodular
fever
septicemia
patient
show
promin
exud
swell
tonsil
cervic
adenopathi
hepatomegali
often
splenomegali
mononucleosi
patient
betahemolyt
group
streptococc
pharyngotonsil
show
prolong
cours
pharyngotonsil
fever
fatigu
tender
cervic
adenopathi
heterophil
antibodi
detect
sever
week
onset
mononucleosi
immunoglobulin
specif
antibodi
capsid
earli
epsteinbarr
viru
antigen
help
earli
diagnosi
mononucleosi
patient
resolv
without
special
treatment
patient
difficulti
swallow
breath
need
hospit
care
cytomegaloviru
caus
mononucleosi
case
hepat
evid
epsteinbarr
virusrel
diseas
test
specif
cytomegaloviru
antibodi
diagnost
import
clinic
present
primari
human
immunodefici
viru
hiv
infect
may
mimic
epsteinbarr
viru
mononucleosi
incub
period
week
acut
hiv
syndrom
present
pharyngotonsil
weight
loss
fever
adenopathi
rash
splenomegali
laboratori
test
often
show
lymphopenia
increas
transaminas
level
test
antihiv
immunoglobulin
often
neg
earli
diseas
stage
detect
hiv
rna
polymeras
chain
reaction
help
provid
diagnosi
import
establish
hiv
diagnosi
earli
possibl
initi
appropri
antivir
therapi
pharyngotonsil
caus
influenza
viru
often
exud
diseas
usual
occur
major
outbreak
often
associ
myalgia
fever
tracheiti
headach
rapid
test
detect
influenza
b
virus
may
use
antivir
therapi
may
reduc
ill
durat
h
seldom
advoc
adenoviru
common
caus
pharyngotonsil
pharyngotonsil
caus
adenoviru
often
present
pharyngoconjunctiv
fever
diseas
otherwis
difficult
distinguish
pharyngotonsil
caus
pathogen
pharyngotonsil
caus
herp
simplex
viru
often
appear
vesicl
ulcer
lesion
mouth
gingiva
diseas
occur
frequent
children
throat
pain
sever
hospit
parenter
nutrit
may
indic
herp
simplex
viru
type
far
common
caus
diseas
herp
simplex
viru
type
present
similar
clinic
manifest
coxsacki
enteroviru
give
rise
pharyngotonsil
character
small
vesicl
surround
red
halo
posterior
palat
diseas
virtual
alway
seen
children
agranulocytosi
leukaemia
might
occasion
start
sever
pharyngotonsil
respond
antibiot
laboratori
blood
test
need
confirm
diagnosi
period
fever
syndrom
character
repeat
episod
pharyngotonsil
cervic
adenopathi
fever
headach
nausea
reduc
gener
condit
elev
creactiv
protein
occur
children
proven
etiolog
pathogen
evidencebas
treatment
tonsillectomi
consid
effect
acut
pharyngotonsil
common
ill
highest
incid
occur
winter
season
virus
account
half
case
pharyngotonsil
betahemolyt
group
streptococci
etiolog
agent
case
higher
figur
observ
winter
month
betahemolyt
group
streptococci
virul
human
pathogen
may
caus
suppur
nonsuppur
complic
sometim
lifethreaten
diseas
necrot
fasciiti
streptococc
toxic
shock
syndrom
sign
symptom
betahemolyt
group
streptococc
infect
includ
tonsillar
exud
tender
anterior
cervic
adenopathi
histori
fever
absenc
cough
find
rather
inconsist
identif
bacterium
cultur
rapid
antigen
test
need
establish
definit
diagnosi
penicillin
v
day
drug
choic
primari
betahemolyt
group
streptococc
pharyngotonsil
although
penicillin
resist
record
betahemolyt
group
streptococci
penicillin
v
treatment
fail
mani
patient
higher
failur
rate
occur
second
cours
penicillin
v
treatment
sometim
necessit
tonsillectomi
factor
potenti
contribut
antibiot
treatment
failur
includ
low
complianc
rate
reinfect
environ
erad
alfahemolyt
streptococci
inhibitori
effect
betahemolyt
group
streptococci
increas
betalactamaseproduc
bacteria
inactiv
drug
penicillintoler
streptococci
low
antibiot
concentr
site
infect
intracellular
betahemolyt
group
streptococci
surviv
therapi
treatment
cephalosporin
clindamycin
report
result
less
frequent
recurr
betahemolyt
group
streptococc
pharyngotonsil
advoc
patient
betahemolyt
group
streptococcu
pharyngotonsil
respond
penicillin
v
treatment
